APTIMA HPV ASSAY
Gen-Probe Incorporated · Decision date Feb 3, 2026
What did the FDA approve?
FDA records P100042/S038 as a supplement to PMA P100042, with the supplement type “Panel Track”. The recorded decision is approval, dated Feb 3, 2026.
FDA approval order statement
The Aptima HPV Assay is an in vitro nucleic acid amplification test for the qualitative detection of E6/E7 viral messenger RNA (mRNA) from 14 high-risk types of human papillomavirus (HPV) in cervical specimens. The high-risk HPV types detected by the assay include: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The Aptima HPV Assay does not differentiate between the 14 high-risk types. Cervical specimens in ThinPrep Pap Test vials containing PreservCyt Solution and collected with broom-type or cytobrush/spatula collection devices* may be tested with the Aptima HPV Assay. The assay is used with the Tigris DTS System or the Panther System.The Aptima HPV Assay is indicated for use for routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (adjunctive screening) with cytology, and HPV primary screening of women to assess the risk for cervical pre-cancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors.Primary HPV screening with the Aptima HPV Assay has only been validated on the Panther System.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Microbiology
- Decision date
- Feb 3, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P100042/S038
- Regulatory pathway
- PMA supplement
- Applicant
- Gen-Probe Incorporated
- Product code
- OYB
- Decision code
- APPR
- Decision date
- Feb 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Kit, rna detection, human papillomavirus.
- Applicant
- Gen-Probe Incorporated
- Product code
- OYB
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P100042/S038 received
Application receipt date recorded by FDA.
P100042/S039 · Related supplement
Aptima HPV Assay 250T (Panther) Box 1; Aptima HPV Assay 250T (Panther) Box 2; Aptima HPV Assay Calibrators; Aptima HPV A
P100042/S038 · FDA decision
Panel Track
Timeline entries are records held by MedtechLedger for P100042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Gen-Probe Incorporated | PMA supplement | Oct 7, 2025 | FDA |
Explore the linked device profile
Other records with product code OYB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Aptima HPV 16 18/45 Genotype AssayP120007/S034 | Gen-Probe Incorporated | PMA supplement | Feb 3, 2026 | FDA |
| Gen-Probe Incorporated | PMA supplement | Oct 7, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Gen-Probe Incorporated
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 10210 Genetic Center Dr., San Diego, CA, 92121
Sources and methodology
- Original FDA record: P100042/S038
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
